What it's for (Indications)
- Aliskiren combined with hydrochlorothiazide (HCTZ) is indicated for the treatment of essential hypertension in adult patients.
- This fixed-dose combination is particularly useful when monotherapy with either aliskiren or hydrochlorothiazide alone is insufficient to achieve adequate blood pressure control.
- It is generally not recommended for initial therapy of hypertension but rather as a step-up treatment in patients whose blood pressure is not optimally managed with a single antihypertensive agent.
- The dual mechanism of action, targeting different pathways involved in blood pressure regulation, offers a comprehensive approach to managing elevated blood pressure, thereby reducing the risk of associated cardiovascular events such as stroke, myocardial infarction, and kidney disease.
- Healthcare providers should assess individual patient needs and existing therapeutic regimens before prescribing this combination to ensure its appropriateness for their specific clinical profile.
Dosage Information
| Type | Guideline |
|---|---|
| Standard | The dosage of aliskiren + hydrochlorothiazide is tailored to the individual patient's blood pressure response and tolerability, with various fixed-dose combinations available. Common starting and maintenance dosages include aliskiren 150 mg / HCTZ 12.5 mg, aliskiren 150 mg / HCTZ 25 mg, aliskiren 300 mg / HCTZ 12.5 mg, and aliskiren 300 mg / HCTZ 25 mg. The medication is typically administered orally once daily. It can be taken with or without food, but it is recommended to take it at approximately the same time each day to maintain consistent drug levels. Dosage adjustments should be made cautiously in patients with renal impairment, and the combination is contraindicated in severe renal impairment (creatinine clearance < 30 mL/min). Hepatic impairment may also require careful consideration. This combination therapy is not recommended for use in children or adolescents, and its use in pregnant women is contraindicated due to potential fetal harm. |
Safety & Warnings
Common Side Effects
- Patients may experience rash, hypokalemia (low blood potassium levels), and rarely anemia (blood disorder with lowered red blood cells).
- If any of these symptoms persist for a long period, consult a physician.
Serious Warnings
- Black Box Warning: WARNING: FETAL TOXICITY. When pregnancy is detected, aliskiren and hydrochlorothiazide therapy must be discontinued as soon as possible. Drugs that act directly on the renin-angiotensin system, including aliskiren, can cause injury and death to the developing fetus, leading to significant morbidity and mortality in the neonate. This includes conditions such as fetal hypotension, anuria, oligohydramnios, and skeletal or respiratory abnormalities, which can be life-threatening. Therefore, strict avoidance is paramount throughout pregnancy due to these serious and irreversible fetal risks. WARNING: AVOID CONCOMITANT USE IN DIABETES OR RENAL IMPAIRMENT. The co-administration of aliskiren with an Angiotensin-Converting Enzyme (ACE) inhibitor or an Angiotensin Receptor Blocker (ARB) is contraindicated in patients with diabetes mellitus, or in patients with moderate to severe renal impairment (defined as an estimated glomerular filtration rate [eGFR] < 60 mL/min/1.73 m²). Clinical trials have demonstrated a significantly increased risk of adverse outcomes, including hyperkalemia, hypotension (which can be symptomatic and severe), and worsening renal function (including acute renal failure), when aliskiren is used concurrently with ACE inhibitors or ARBs in these vulnerable patient populations. These serious adverse events can necessitate hospitalization and may lead to irreversible harm or even death. Therefore, dual blockade of the renin-angiotensin system with aliskiren and an ACE inhibitor or ARB in these specific patient groups must be strictly avoided due to the documented heightened safety risks and lack of demonstrated additional benefit.
- Avoid driving when taking this medicine as it may affect your ability to drive.
- Use with extreme caution in patients taking diuretics, those on a low sodium diet, or individuals who are easily dehydrated.
How it Works (Mechanism of Action)
The therapeutic effect of aliskiren + hydrochlorothiazide stems from the synergistic actions of its two components in lowering blood pressure. Aliskiren is a direct renin inhibitor, meaning it directly binds to the active site of renin, an enzyme primarily produced by the kidneys. This binding inhibits the catalytic conversion of angiotensinogen to angiotensin I, thereby reducing the entire activity of the Renin-Angiotensin-Aldosterone System (RAAS). Consequently, the formation of angiotensin II, a potent vasoconstrictor and stimulator of aldosterone secretion, is decreased. This leads to vasodilation, reduced sodium and water reabsorption, and ultimately a decrease in blood pressure. Hydrochlorothiazide (HCTZ), on the other hand, is a thiazide diuretic that acts on the distal convoluted tubule of the kidney. It inhibits the sodium-chloride symporter, leading to increased urinary excretion of sodium, chloride, and water, while also increasing potassium and bicarbonate excretion. This diuretic action results in a reduction of extracellular fluid volume and a subsequent decrease in cardiac output and blood pressure. The combination provides a comprehensive approach to blood pressure reduction, with aliskiren addressing RAAS overactivity and HCTZ managing fluid volume, resulting in a more pronounced and sustained antihypertensive effect than either agent alone.
Commercial Brands (Alternatives)
No other brands found for this formula.